Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements. This article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprint requires authorization.
From the beginning of the year to date,siRNAThis technology field, once considered a "niche frontier," is proving its weight in the mainstream pharmaceutical landscape in a nearly radical way. Recently, the siRNA sector witnessed two major licensing deals exceeding $1 billion each, pushing this trend to a new climax.$1.005 Billion: SiranBioALK7 siRNAAuthorize GSKMay 6, 2026SiranBio Announces Global Exclusive License Agreement with GSK for SA030(Excluding mainland China, Hong Kong, Macao and Taiwan).SA030 is a potential first-in-class, long-acting small interfering RNA (siRNA) oligonucleotide., which is currently in the development stage, is intended for the treatment of metabolic and cardiovascular diseases. SA030 has recently entered Phase I clinical trials, targeting Activin Receptor-Like Kinase 7 (ALK7) — an established therapeutic mechanism for cardiometabolic diseases. Given the unresolved cardiometabolic risks in various chronic conditions, this program holds significant clinical and market potential.According to the agreement, GlaxoSmithKline (GSK) will pay an upfront fee, as well as future milestone payments based on the successful achievement of development, registration, and commercialization goals.Up to $1.005 billion in total; At the same time, a tiered royalty will be paid based on global net product sales (excluding mainland China, Hong Kong, Macao, and Taiwan regions). SiranBio will lead the clinical development of SA030 until the completion of Phase I clinical trials. Afterward, GSK will assume the responsibilities for development, regulatory submissions, and commercialization outside of mainland China, Hong Kong, Macao, and Taiwan regions.Preclinical studies have shown that SA030 possesses differentiated long-acting properties, which can intervene in fundamental inflammation associated with cardiometabolic risks through adipocyte-targeted delivery and a low-frequency dosing regimen. SA030 has a complementary and unique mechanism to GLP-1 agonists and SGLT2 inhibitors, supporting potential future combination therapy strategies to reduce residual cardiometabolic risks not fully addressed by existing therapies.$1 billion: ArrowheadPNPLA3 siRNAAuthorizationMadrigal May 5, 2026Madrigal Pharmaceuticals, a biopharmaceutical company focused on providing novel therapies for Metabolic Dysfunction-Associated Steatohepatitis (MASH),Announcement of Exclusive Global Licensing Agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3ARO-PNPLA3 is a small interfering RNA (siRNA) drug in the clinical stage, targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3), which is a key genetic driver of MASH.Arrowhead has granted Madrigal an exclusive global license for ARO-PNPLA3 for the drug's subsequent development, manufacturing, and commercialization. Arrowhead will receive$25 million upfront payment, if specific milestone events are achieved, additional gains will be obtained.Up to $975 million in additional payments, as well as royalties based on net sales.The licensing of ARO-PNPLA3 adds a precision medicine option targeting high-risk MASH patients to Madrigal's product pipeline. PNPLA3 I148M is a recognized genetic factor in MASH progression, associated with increased liver fat, inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Approximately 30% of MASH patients with moderate to advanced fibrosis (equivalent to F2 to F3 stage fibrosis) carry two identical copies of this variant (i.e., homozygous patients), and this variant is highly prevalent in the Hispanic population.Phase I trial provides proof-of-concept for ARO-PNPLA3 as a potential precision medicine approach for MASH:A Phase I First-in-Human, Double-Blind, Placebo-Controlled Trial of ARO-PNPLA3 was Conducted in the United States, Enrolling 55 Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Who Were Homozygous or Heterozygous Carriers of the PNPLA3 I148M Variant. Approximately 93% of the Participants Were Hispanic or Latino. The Study Results Were Published in The New England Journal of Medicine, and the Data Showed:- In PNPLA3 I148M homozygous patients, liver fat was reduced by up to 46% (measured by MRI-PDFF) 12 weeks after a single administration of the highest tested dose.- Rapid onset, fat reduction can be observed in 6 weeks, with effects lasting at least 24 weeks.- No clinically significant adverse events were observed.- No change in liver fat content was observed in heterozygous participants at any study dose.- The results of the second Phase I trial (n=9) conducted in Japan support the aforementioned findings.Madrigal currently has seven siRNA projects in its pipeline.Reference: Company Announcement
Mastering CAR-T Therapy, Stem Cell Therapy, GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
